Prosecution Insights
Last updated: August 14, 2026

Health Research Inc.

11 pending office actions • 10 art units • 11 examiners • 0 of 11 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days

Portfolio Summary

11
Total Pending OAs
6
Non-Final OAs
4
Final Rejections
1
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

2
Overdue
0
Due this week
1
Due this month
1
Due in next 60 days
1
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (2)Due ≤ 30 days (1)Due ≤ 60 days (1)Due later (1)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

5
Hard (45%)
4
Medium (36%)
2
Easy (18%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§101 + other1 (9%)
§103 only2 (18%)
§102 only1 (9%)
§112 only1 (9%)
Double-patenting only1 (9%)
Double-patenting + other1 (9%)
Multi-statute (no §101)4 (36%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

7
Life Sciences
64% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
3
Mechanical / Eng
27% of docket
1
Business / Other
9% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

110 h
Manual time on pending OAs
22 h
Time saved (low, 20%)
38 h
Time saved (mid, 35%)
1.0 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
GRASER, JENNIFER E 1 76.5% +23.6%
PAGUIO FRISING, MICHELLE F 1 70.8% +40.3%
REDDIG, PETER J 1 58.1% +39.9%
PETERS, ALEC JON 1 67.5% +56.0%
RZECZYCKI, PHILLIP MATTHEW 1 63.0% +39.1%
MULLINS, JESSICA LYNN 1 50.0% +35.4%
JOHANNSEN, DIANA B 1 53.3% +42.5%
RESTAINO, ANDREW PETER 1 73.0% +40.3%
HUDSON, AMY ROSE 1 75.0% +11.4%
FONSECA LOPEZ, FRANCINI ALVARENGA 1 33.3% +44.4%

Hard Cases (5)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.

App #TitleExaminerDue in
17523079 ANTI-MICROBIAL PEPTIDES AND METHOD FOR DESIGNING NOVEL ANTI-MICROBIAL PEPTIDES FONSECA LOPEZ, FRANCINI ALVARENGA 34d
18093066 METHODS RELATED TO BRONCHIAL PREMALIGNANT LESION SEVERITY AND PROGRESSION JOHANNSEN, DIANA B 75d
18439315 METHOD FOR PROPHYLAXIS AND/OR TREATMENT OF ErbB2 POSITIVE CANCERS REDDIG, PETER J
18162995 METHOD AND SYSTEM FOR CONCURRENT PHOTOTHERMAL ABLATION AND INTERSTITIAL PHOTODYNAMIC THERAPY MULLINS, JESSICA LYNN
17638518 REACTIVATING P53 MUTANTS FOR CANCER TREATMENT BY TARGETING PROLIDASE (PEPD) HUDSON, AMY ROSE

Interview Candidates (10)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
18253384 COMPOUNDS AND METHODS TO TARGET GLUCOSE-STIMULATED PHOSPHOHISTIDINE SIGNALING AND ESOPHAGEAL CANCER GROWTH RZECZYCKI, PHILLIP MATTHEW 60d overdue
18001001 JOINTED DEVICE FOR AUTOMATIC SUTURE AND METHOD FOR SAME RESTAINO, ANDREW PETER 5d overdue
17523079 ANTI-MICROBIAL PEPTIDES AND METHOD FOR DESIGNING NOVEL ANTI-MICROBIAL PEPTIDES FONSECA LOPEZ, FRANCINI ALVARENGA 34d
18093066 METHODS RELATED TO BRONCHIAL PREMALIGNANT LESION SEVERITY AND PROGRESSION JOHANNSEN, DIANA B 75d
18830683 COMPOSITION AND METHOD FOR GENERATING IMMUNITY TO BORRELIA BURGDORFERI GRASER, JENNIFER E
18691035 METHOD OF MITIGATION OF INJURIES CAUSED BY SYSTEMIC GENOTOXIC STRESS PAGUIO FRISING, MICHELLE F
18439315 METHOD FOR PROPHYLAXIS AND/OR TREATMENT OF ErbB2 POSITIVE CANCERS REDDIG, PETER J
18259763 ANTI-SURVIVIN ANTIBODIES FOR TREATMENT OF AUTOIMMUNE DISEASES PETERS, ALEC JON

Top Art Units

Art UnitApps
1651 1
1642 1
1641 1
1625 1
3792 1
1682 1
3771 1
1636 1
1685 1
3785 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18830683 COMPOSITION AND METHOD FOR GENERATING IMMUNITY TO BORRELIA BURGDORFERI GRASER, JENNIFER E DP Non-Final OA Pending Sep 11, 2024
18691035 METHOD OF MITIGATION OF INJURIES CAUSED BY SYSTEMIC GENOTOXIC STRESS PAGUIO FRISING, MICHELLE F 1651 §112 Non-Final OA Pending Mar 11, 2024
18439315 METHOD FOR PROPHYLAXIS AND/OR TREATMENT OF ErbB2 POSITIVE CANCERS REDDIG, PETER J 1642 §101§102§103DP Non-Final OA Pending Feb 12, 2024
18259763 ANTI-SURVIVIN ANTIBODIES FOR TREATMENT OF AUTOIMMUNE DISEASES PETERS, ALEC JON 1641 §102§103§112DP Non-Final OA Pending Jun 28, 2023
18253384 COMPOUNDS AND METHODS TO TARGET GLUCOSE-STIMULATED PHOSPHOHISTIDINE SIGNALING AND ESOPHAGEAL CANCER GROWTH RZECZYCKI, PHILLIP MATTHEW 1625 §102 Final Rejection 60d overdue Pending May 17, 2023
18162995 METHOD AND SYSTEM FOR CONCURRENT PHOTOTHERMAL ABLATION AND INTERSTITIAL PHOTODYNAMIC THERAPY MULLINS, JESSICA LYNN 3792 §102§103 Non-Final OA Pending Feb 01, 2023
18093066 METHODS RELATED TO BRONCHIAL PREMALIGNANT LESION SEVERITY AND PROGRESSION JOHANNSEN, DIANA B 1682 §102§103 Non-Final OA 75d Pending Jan 04, 2023
18001001 JOINTED DEVICE FOR AUTOMATIC SUTURE AND METHOD FOR SAME RESTAINO, ANDREW PETER 3771 §103 Final Rejection 5d overdue Pending Dec 07, 2022
17638518 REACTIVATING P53 MUTANTS FOR CANCER TREATMENT BY TARGETING PROLIDASE (PEPD) HUDSON, AMY ROSE 1636 §103§112 Non-Final OA Pending Feb 25, 2022
17523079 ANTI-MICROBIAL PEPTIDES AND METHOD FOR DESIGNING NOVEL ANTI-MICROBIAL PEPTIDES FONSECA LOPEZ, FRANCINI ALVARENGA 1685 §103§112 Final Rejection 34d Pending Nov 10, 2021
16979464 INDUCTION SPACER FOR INHALER MOON, MATTHEW RYAN 3785 §103 Final Rejection 14d Pending Sep 09, 2020

Managing Health Research Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month